Persbericht Biocartis Group NV: Voltooiing van alomvattende herkapitalisatie transacties
16 janv. 2023 11h40 HE
|
Biocartis NV
PERSBERICHT: GEREGLEMENTEERDE INFORMATIE16 januari 2023, 17:40 CET Voltooiing van alomvattende herkapitalisatie transacties Mechelen, België, 16 januari 2023 – Biocartis Group NV (de "Vennootschap"...
PDS Biotech to Participate at the B. Riley Securities 3rd Annual Oncology Conference
13 janv. 2023 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Jan. 13, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
Global Cell Therapy Market to Surpass US$ 1,391.94 Million by 2030, Says Coherent Market Insights (CMI)
12 janv. 2023 09h00 HE
|
CMI
Burlingame, Jan. 12, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global cell therapy market is estimated to be valued at US$ 786.50 Mn in 2022 and is expected to exhibit a...
POINT Biopharma Completes Randomization in PNT2002’s Phase 3 SPLASH Trial
12 janv. 2023 08h30 HE
|
POINT Biopharma
INDIANAPOLIS, Jan. 12, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors
11 janv. 2023 08h00 HE
|
Aprea Therapeutics
DOYLESTOWN, Pa., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics...
Oncology Molecular Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2029
11 janv. 2023 07h55 HE
|
Fortune Business Insights
Pune, India, Jan. 11, 2023 (GLOBE NEWSWIRE) -- The market size for Oncology Molecular Diagnostics is expected to be large and growing due to increasing incidences of cancer and the use of...
Valo Therapeutics selects Exothera to develop large-scale oncolytic Adenovirus manufacturing
11 janv. 2023 02h00 HE
|
Valo Therapeutics LTD
HELSINKI, Finland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced it...
Novotech Acquires European CRO – Strengthens Global Operations
09 janv. 2023 11h33 HE
|
Novotech
SINGAPORE, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Novotech announced today the acquisition of EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important...
Calidi Biotherapeutics and First Light Acquisition Group (FLAG) Announce Merger Agreement to Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies
09 janv. 2023 10h33 HE
|
First Light Acquisition Group; Calidi Biotherapeutics, Inc.
-Total gross proceeds from transaction, before payment of transaction expenses, expected to be up to $82 million assuming no redemptions, combining a possible PIPE financing of up to $40 million and...
Ractigen Therapeutics Announces the Appointment of Harri Järveläinen as Chief Operating Officer
09 janv. 2023 07h00 HE
|
Ractigen Therapeutics
SUZHOU, China, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, Inc. announced today that Dr. Harri Järveläinen has been appointed Chief Operating Officer of the Company. "I am thrilled to...